Comprehensive Stock Comparison
Compare Abivax S.A. (ABVX) vs TG Therapeutics, Inc. (TGTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ABVX | 133.5% revenue growth vs TGTX's 40.8% |
| Quality / Margins | TGTX | 13.3% net margin vs ABVX's -21.9% |
| Stability / Safety | TGTX | Beta 0.43 vs ABVX's 1.07, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ABVX | +14.8% vs TGTX's 0.0% |
| Efficiency (ROA) | TGTX | 8.6% ROA vs ABVX's -277.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Abivax is a clinical-stage biotechnology company developing novel therapies for inflammatory diseases, infectious diseases, and cancer. It generates revenue primarily through research grants and partnerships while advancing its lead candidate ABX464 through clinical trials for ulcerative colitis, Crohn's disease, and other inflammatory conditions. The company's competitive advantage lies in its proprietary small molecule platform technology that targets RNA biology to modulate inflammation and viral replication.
TG Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. It generates revenue primarily from sales of its FDA-approved multiple sclerosis drug BRIUMVI (ublituximab) — its first commercial product — with future revenue expected from its pipeline of oncology candidates. The company's competitive advantage lies in its glycoengineered antibody platform technology, which creates potentially more effective and convenient treatments for complex diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
TGTX leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). ABVX leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
TGTX is the larger business by revenue, generating $454M annually — 30.0x ABVX's $15M. TGTX is the more profitable business, keeping 13.3% of every revenue dollar as net income compared to ABVX's -21.9%. On growth, TGTX holds the edge at +92.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| RevenueTrailing 12 months | $15M | $454M |
| EBITDAEarnings before interest/tax | -$358M | $86M |
| Net IncomeAfter-tax profit | -$332M | $60M |
| Free Cash FlowCash after capex | -$250M | -$59M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +87.0% |
| Operating MarginEBIT ÷ Revenue | -23.7% | +18.9% |
| Net MarginNet income ÷ Revenue | -21.9% | +13.3% |
| FCF MarginFCF ÷ Revenue | -16.5% | -13.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -40.6% | +92.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -144.6% | +2.9% |
Valuation Metrics
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| Market CapShares × price | $9.6B | $4.8B |
| Enterprise ValueMkt cap + debt − cash | $9.5B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -36.72x | 200.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 114.40x |
| Price / SalesMarket cap ÷ Revenue | 753.36x | 14.45x |
| Price / BookPrice ÷ Book value/share | 159.73x | 21.70x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
TGTX delivers a 21.9% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-149 for ABVX. TGTX carries lower financial leverage with a 1.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to ABVX's 2.40x. On the Piotroski fundamental quality scale (0–9), ABVX scores 4/9 vs TGTX's 3/9, reflecting mixed financial health.
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| ROE (TTM)Return on equity | -149.0% | +21.9% |
| ROA (TTM)Return on assets | -2.8% | +8.6% |
| ROICReturn on invested capital | — | +13.3% |
| ROCEReturn on capital employed | -98.5% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 2.40x | 1.14x |
| Net DebtTotal debt minus cash | -$47M | $74M |
| Cash & Equiv.Liquid assets | $144M | $180M |
| Total DebtShort + long-term debt | $97M | $254M |
| Interest CoverageEBIT ÷ Interest expense | -21.56x | 3.11x |
Total Returns (with DRIP)
A $10,000 investment in ABVX five years ago would be worth $146,121 today (with dividends reinvested), compared to $6,687 for TGTX. Over the past 12 months, ABVX leads with a +1479.2% total return vs TGTX's 0.0%. The 3-year compound annual growth rate (CAGR) favors ABVX at 144.5% vs TGTX's 23.4% — a key indicator of consistent wealth creation.
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| YTD ReturnYear-to-date | -9.3% | +2.8% |
| 1-Year ReturnPast 12 months | +1479.2% | 0.0% |
| 3-Year ReturnCumulative with dividends | +1361.2% | +87.8% |
| 5-Year ReturnCumulative with dividends | +1361.2% | -33.1% |
| 10-Year ReturnCumulative with dividends | +1361.2% | +261.2% |
| CAGR (3Y)Annualised 3-year return | +144.5% | +23.4% |
Risk & Volatility
TGTX is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than ABVX's 1.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABVX currently trades 81.5% from its 52-week high vs TGTX's 64.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.07x | 0.43x |
| 52-Week HighHighest price in past year | $148.83 | $46.48 |
| 52-Week LowLowest price in past year | $4.77 | $25.28 |
| % of 52W HighCurrent price vs 52-week peak | +81.5% | +64.7% |
| RSI (14)Momentum oscillator 0–100 | 45.5 | 58.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.7M |
Analyst Outlook
Wall Street rates ABVX as "Buy" and TGTX as "Buy". Consensus price targets imply 64.5% upside for TGTX (target: $50) vs 17.5% for ABVX (target: $143).
| Metric | ABVXAbivax S.A. | TGTXTG Therapeutics, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $142.50 | $49.50 |
| # AnalystsCovering analysts | 8 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Oct 23 | Feb 26 | Change |
|---|---|---|---|
| Abivax S.A. (ABVX) | 100 | 1,342.89 | +1242.9% |
| TG Therapeutics, In… (TGTX) | 100 | 288.34 | +188.3% |
Abivax S.A. (ABVX) returned +1.4K% over 5 years vs TG Therapeutics, In… (TGTX)'s -33%. A $10,000 investment in ABVX 5 years ago would be worth $146,121 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Abivax S.A. (ABVX) | $42000.00 | $11M | +25595.2% |
| TG Therapeutics, In… (TGTX) | $152381.00 | $329M | +215808.8% |
Abivax S.A.'s revenue grew from $0M (2015) to $11M (2024) — a 85.3% CAGR. TG Therapeutics, Inc.'s revenue grew from $0M (2015) to $329M (2024) — a 134.7% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Abivax S.A. (ABVX) | -379.9% | -16.3% | +95.7% |
| TG Therapeutics, In… (TGTX) | -413.1% | 7.1% | +101.7% |
Abivax S.A.'s net margin went from -380% (2015) to -16% (2024). TG Therapeutics, Inc.'s net margin went from -413% (2015) to 7% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Abivax S.A. (ABVX) | -1.64 | -2.8 | -70.7% |
| TG Therapeutics, In… (TGTX) | -1.38 | 0.15 | +110.9% |
Abivax S.A.'s EPS grew from $-1.64 (2015) to $-2.80 (2024). TG Therapeutics, Inc.'s EPS grew from $-1.38 (2015) to $0.15 (2024).
Chart 5Free Cash Flow — 5 Years
Abivax S.A. generated $-155M FCF in 2024 (-227% vs 2021). TG Therapeutics, Inc. generated $-41M FCF in 2024 (+86% vs 2021).
ABVX vs TGTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ABVX or TGTX a better buy right now?
TG Therapeutics, Inc. (TGTX) offers the better valuation at 200.6x trailing P/E (19.4x forward), making it the more compelling value choice. Analysts rate Abivax S.A. (ABVX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABVX or TGTX?
Over the past 5 years, Abivax S.A. (ABVX) delivered a total return of +1361%, compared to -33.1% for TG Therapeutics, Inc. (TGTX). A $10,000 investment in ABVX five years ago would be worth approximately $146K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ABVX returned +1361% versus TGTX's +261.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABVX or TGTX?
By beta (market sensitivity over 5 years), TG Therapeutics, Inc. (TGTX) is the lower-risk stock at 0.43β versus Abivax S.A.'s 1.07β — meaning ABVX is approximately 146% more volatile than TGTX relative to the S&P 500. On balance sheet safety, TG Therapeutics, Inc. (TGTX) carries a lower debt/equity ratio of 114% versus 2% for Abivax S.A. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ABVX or TGTX?
TG Therapeutics, Inc. (TGTX) is the more profitable company, earning 7.1% net margin versus -1633.1% for Abivax S.A. — meaning it keeps 7.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 12.7% versus -1602.9% for ABVX. At the gross margin level — before operating expenses — ABVX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ABVX or TGTX more undervalued right now?
Analyst consensus price targets imply the most upside for TGTX: 64.5% to $49.50.
06Which pays a better dividend — ABVX or TGTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ABVX or TGTX better for a retirement portfolio?
For long-horizon retirement investors, Abivax S.A. (ABVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.07), +1361% 10Y return). Both have compounded well over 10 years (ABVX: +1361%, TGTX: +261.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ABVX and TGTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.